盛禾生物-B2024年度亏损减少至约8000万元

格隆汇
Mar 31

格隆汇3月31日丨盛禾生物-B(02898.HK)公告,2024年度,集团其他收入由上年度约人民币21.0百万元减少约54.8%至报告期约人民币9.5百万元,主要由于集团于报告期间收到的政府补助减少。于报告期间研发费用由2023年的约人民币43.0百万元增加至本报告期间的约人民币71.1百万元,乃主要由于以股份为基础的薪酬的增加。公司的期内亏损由截至2023年12月31日止年度的约人民币132.7...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10